PRTC - PureTech Health plc
17.26
0.120 0.695%
Share volume: 107
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.10%
PREVIOUS CLOSE
CHG
CHG%
$17.14
0.12
0.01%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
0 0%
1 Month
-12.74%
3 Months
-8.63%
6 Months
-8.63%
1 Year
-8.63%
2 Year
-8.63%
Key data
Stock price
$17.26
DAY RANGE
$16.81 - $17.28
52 WEEK RANGE
$13.30 - $20.00
52 WEEK CHANGE
-$8.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-28-2025
Company detail
CEO: Daphne Zohar
Region: US
Website: puretechhealth.com
Employees: 100
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: puretechhealth.com
Employees: 100
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
PureTech Health plc discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease. It also provides hematopoietic stem cell based therapies for patients with blood cancer.
Recent news
